Track PHVS and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Pharvaris BV
Grafenauweg 8, Zug, Switzerland, 6300
IPO
2021
Employees
134
Industry
Biotechnology
Sector
Healthcare
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20269-9
0
Analyst Ratings
3 analysts covering
Buy67%recommend buy
Buy
2
Hold
0
Sell
1